Trials / Completed
CompletedNCT01267357
P16 Staining as Prognostic Biomarker in Serous Papillary Endometrial Cancer
Expression of the P16 Protein in Serous Papillary Endometrial Cancer, and Its Clinical and Prognostic Significance
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 62 (actual)
- Sponsor
- Rambam Health Care Campus · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
P16 is a tumor suppressor protein implicated in serous papillary endometrial carcinoma. Evidence from previous trials indicates that it may be used as a diagnostic biomarker distinguishing this disease from endometrioid endometrial cancer. Additional evidence points to its prognostic value. The current study will evaluate p16 both as a diagnostic tool for serous papillary endometrial cancer and as a prognostic biomarker. following anonymization, histology blocks will be microtomed and stained for P16 and P53 proteins. Blocks from endometrioid endometrial cancer will be used as a control group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | no intervention |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2010-11-01
- First posted
- 2010-12-28
- Last updated
- 2010-12-28
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01267357. Inclusion in this directory is not an endorsement.